FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as GSK.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiology · Cardiac Safety
- Sub-indication
- Hypertension
Related signal: GSK's Bepirovirsen Study Evaluates Cardiac Conduction Impact in Healthy Volunteers